CLR 1404 I-124

Drug Profile

CLR 1404 I-124

Alternative Names: 124I-CLR1404; CLR-124; CLR1404 I-124; I-124-CLR1404; I124-NM404; LIGHT

Latest Information Update: 02 Jan 2017

Price : $50

At a glance

  • Originator University of Michigan Medical School
  • Developer Cellectar Biosciences; University of Wisconsin-Madison
  • Class Imaging agents; Phospholipids; Radiopharmaceutical diagnostics; Small molecules
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Glioblastoma
  • Phase I/II Brain cancer; Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 20 Dec 2016 Cellectar Biosciences receives patent allowance for CLR 1404 I-124 in USA
  • 01 May 2016 Cellectar terminates a phase I/II trial in Solid tumours (diagnosis) in USA (NCT01662284)
  • 21 Sep 2015 CLR 1404 I-124 is still in phase I/II trials for Brain cancer, Non-small cell lung cancer and other Solid tumours in the USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top